Yazi Yang

Yazi Yang

Auto-generated profile, based on publicly available information

Yazi Yang

Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
YYYazi Yang
Yazi Yang
SQSen Qin
Sen Qin
MYMengyu Yang
Mengyu Yang
TWTing Wang
Ting Wang
RFRu Feng
Ru Feng
HLHui Liu
Hui Liu
Purpose: The purpose of this study was to investigate the remodeling of the multiple myeloma microenvironment after B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T (CAR-T) cell therapy. Experimental Design: We performed single-cell RNA sequencing on paired bone marrow specimens (n = 14) from seven patients with multiple myeloma before (i.e., baseline, “day −4”) and after (i.e., “day 28”) lymphodepleted BCMA CAR-T cell therapy. Results: Our analysis revealed heterogeneity in gene expression profiles among multiple myeloma cells, even those harboring the same cytogenetic abnormalities. The best overall responses of patients over the 15-month follow-up are positively correlated with the abundance and targeted cytotoxic activity of CD8+ effector CAR-T cells on day 28 after CAR-T cell infusion. Additionally, favorable responses are associated with attenuated immunosuppression mediated by regulatory T cells, enhanced CD8+ effector T-cell cytotoxic activity, and elevated type 1 conventional dendritic cell (DC) antigen presentation ability. DC re-clustering inferred intramedullary-originated type 3 conventional DCs with extramedullary migration. Cell–cell communication network analysis indicated that BCMA CAR-T therapy mitigates BAFF/GALECTIN/MK pathway–mediated immunosuppression and activates MIF pathway–mediated anti–multiple myeloma immunity. Conclusions: Our study sheds light on multiple myeloma microenvironment dynamics after BCMA CAR-T therapy, offering clues for predicting treatment responsivity.

13 September 2024
Verified
Other
Open access
PDF file
YYYazi Yang
Yazi Yang
SQSen Qin
Sen Qin
MYMengyu Yang
Mengyu Yang
TWTing Wang
Ting Wang
RFRu Feng
Ru Feng
HLHui Liu
Hui Liu
Supplementary Figure S6. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.

13 September 2024
Verified
Other
Open access
PDF file
YYYazi Yang
Yazi Yang
SQSen Qin
Sen Qin
MYMengyu Yang
Mengyu Yang
TWTing Wang
Ting Wang
RFRu Feng
Ru Feng
HLHui Liu
Hui Liu
Supplementary Table S2. Clinical Assessment of MM Patients after BCMA CAR-T Therapy.

13 September 2024
Verified
Other
Open access
PDF file
YYYazi Yang
Yazi Yang
SQSen Qin
Sen Qin
MYMengyu Yang
Mengyu Yang
TWTing Wang
Ting Wang
RFRu Feng
Ru Feng
HLHui Liu
Hui Liu
Supplementary Figure S7. BCMA CAR-T Therapy Attenuates BAFF/GALECTIN/MK Pathway-mediated Immunosuppression and Activates MIF Pathway-mediated Anti-MM Immunity.

13 September 2024
Verified
Other
Open access
YYYazi Yang
Yazi Yang
SQSen Qin
Sen Qin
MYMengyu Yang
Mengyu Yang
TWTing Wang
Ting Wang
RFRu Feng
Ru Feng
HLHui Liu
Hui Liu
Purpose:The purpose of this study was to investigate the remodeling of the multiple myeloma microenvironment after B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T (CAR-T) cell therapy.Experimental Design:We performed single-cell RNA sequencing on paired bone marrow specimens (n = 14) from seven patients with multiple myeloma before (i.e., baseline, “day −4”) and after (i.e., “day 28”) lymphodepleted BCMA CAR-T cell therapy.Results:Our analysis revealed heterogeneity in gene expression profiles among multiple myeloma cells, even those harboring the same cytogenetic abnormalities. The best overall responses of patients over the 15-month follow-up are positively correlated with the abundance and targeted cytotoxic activity of CD8+ effector CAR-T cells on day 28 after CAR-T cell infusion. Additionally, favorable responses are associated with attenuated immunosuppression mediated by regulatory T cells, enhanced CD8+ effector T-cell cytotoxic activity, and elevated type 1 conventional dendritic cell (DC) antigen presentation ability. DC re-clustering inferred intramedullary-originated type 3 conventional DCs with extramedullary migration. Cell–cell communication network analysis indicated that BCMA CAR-T therapy mitigates BAFF/GALECTIN/MK pathway–mediated immunosuppression and activates MIF pathway–mediated anti–multiple myeloma immunity.Conclusions:Our study sheds light on multiple myeloma microenvironment dynamics after BCMA CAR-T therapy, offering clues for predicting treatment responsivity.

13 September 2024
Verified
Other
Open access
PDF file
YYYazi Yang
Yazi Yang
SQSen Qin
Sen Qin
MYMengyu Yang
Mengyu Yang
TWTing Wang
Ting Wang
RFRu Feng
Ru Feng
HLHui Liu
Hui Liu
Supplementary Figure S2. Clustering of the Cells within the MM Microenvironment.